Log in
NASDAQ:KALV

Kalvista Pharmaceuticals Stock Forecast, Price & News

$12.89
+0.14 (+1.10 %)
(As of 09/28/2020 06:20 AM ET)
Add
Compare
Today's Range
$12.57
Now: $12.89
$12.94
50-Day Range
$11.21
MA: $13.00
$13.99
52-Week Range
$5.61
Now: $12.89
$18.96
Volume31,500 shs
Average Volume119,969 shs
Market Capitalization$230.83 million
P/E RatioN/A
Dividend YieldN/A
Beta2.44
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, an intravitreally administered plasma kallikrein inhibitor that is in Phase II clinical trials for the treatment of DME; and KVD900, a potent inhibitor of plasma kallikrein, which is in Phase I clinical trial for treating HAE. The company is headquartered in Cambridge, Massachusetts.
Read More
Kalvista Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.48 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KALV
CUSIPN/A
Phone857-999-0075

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.69 million
Book Value$4.69 per share

Profitability

Net Income$-29,120,000.00
Net Margins-229.45%

Miscellaneous

Employees33
Market Cap$230.83 million
Next Earnings Date12/1/2020 (Estimated)
OptionableNot Optionable
$12.89
+0.14 (+1.10 %)
(As of 09/28/2020 06:20 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KALV News and Ratings via Email

Sign-up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kalvista Pharmaceuticals (NASDAQ:KALV) Frequently Asked Questions

How has Kalvista Pharmaceuticals' stock price been impacted by COVID-19 (Coronavirus)?

Kalvista Pharmaceuticals' stock was trading at $8.86 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, KALV shares have increased by 45.5% and is now trading at $12.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Kalvista Pharmaceuticals?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kalvista Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kalvista Pharmaceuticals
.

When is Kalvista Pharmaceuticals' next earnings date?

Kalvista Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, December 1st 2020.
View our earnings forecast for Kalvista Pharmaceuticals
.

How were Kalvista Pharmaceuticals' earnings last quarter?

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) announced its quarterly earnings data on Monday, September, 14th. The specialty pharmaceutical company reported ($0.61) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.60) by $0.01. Kalvista Pharmaceuticals had a negative net margin of 229.45% and a negative return on equity of 36.04%.
View Kalvista Pharmaceuticals' earnings history
.

What price target have analysts set for KALV?

3 analysts have issued 1 year target prices for Kalvista Pharmaceuticals' stock. Their forecasts range from $25.00 to $30.00. On average, they expect Kalvista Pharmaceuticals' share price to reach $27.50 in the next twelve months. This suggests a possible upside of 113.3% from the stock's current price.
View analysts' price targets for Kalvista Pharmaceuticals
.

Who are some of Kalvista Pharmaceuticals' key competitors?

What other stocks do shareholders of Kalvista Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kalvista Pharmaceuticals investors own include Heron Therapeutics (HRTX), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), SCYNEXIS (SCYX), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Aldeyra Therapeutics (ALDX), Catalyst Pharmaceuticals (CPRX), Corbus Pharmaceuticals (CRBP) and Pfizer (PFE).

Who are Kalvista Pharmaceuticals' key executives?

Kalvista Pharmaceuticals' management team includes the following people:
  • Mr. Thomas Andrew Crockett, CEO & Director (Age 44)
  • Mr. Benjamin L. Palleiko, Chief Bus. Officer & CFO (Age 53)
  • Mr. Andreas Maetzel M.D., M.Sc., Ph.D., Sr. VP of Medical (Age 56)
  • Mr. John B. McKune, VP of Fin. (Age 43)
  • Dr. Edward P. Feener, Chief Scientific Officer (Age 59)

What is Kalvista Pharmaceuticals' stock symbol?

Kalvista Pharmaceuticals trades on the NASDAQ under the ticker symbol "KALV."

Who are Kalvista Pharmaceuticals' major shareholders?

Kalvista Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (9.88%), Ikarian Capital LLC (6.24%), Logos Global Management LP (3.15%), Opaleye Management Inc. (2.59%), International Biotechnology Trust PLC (0.99%) and Nuveen Asset Management LLC (0.62%). Company insiders that own Kalvista Pharmaceuticals stock include Albert Cha, Andreas Maetzel, Benjamin L Palleiko, Christopher Yea, Daniel B Soland, Edward P Feener, Life Sciences Fund Iv (Gp) Sv, Svlsf Iv, Llc, Thomas Andrew Crockett and Venrock Healthcare Capital Par.
View institutional ownership trends for Kalvista Pharmaceuticals
.

Which institutional investors are selling Kalvista Pharmaceuticals stock?

KALV stock was sold by a variety of institutional investors in the last quarter, including International Biotechnology Trust PLC, FMR LLC, Alps Advisors Inc., Algert Global LLC, UBS Group AG, PDT Partners LLC, and Bank of America Corp DE. Company insiders that have sold Kalvista Pharmaceuticals company stock in the last year include Christopher Yea, and Thomas Andrew Crockett.
View insider buying and selling activity for Kalvista Pharmaceuticals
.

Which institutional investors are buying Kalvista Pharmaceuticals stock?

KALV stock was acquired by a variety of institutional investors in the last quarter, including Logos Global Management LP, Opaleye Management Inc., Ikarian Capital LLC, Nuveen Asset Management LLC, Goldman Sachs Group Inc., Jacobs Levy Equity Management Inc., California Public Employees Retirement System, and Dupont Capital Management Corp. Company insiders that have bought Kalvista Pharmaceuticals stock in the last two years include Albert Cha, and Daniel B Soland.
View insider buying and selling activity for Kalvista Pharmaceuticals
.

How do I buy shares of Kalvista Pharmaceuticals?

Shares of KALV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kalvista Pharmaceuticals' stock price today?

One share of KALV stock can currently be purchased for approximately $12.89.

How big of a company is Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals has a market capitalization of $230.83 million and generates $12.69 million in revenue each year. The specialty pharmaceutical company earns $-29,120,000.00 in net income (profit) each year or ($1.64) on an earnings per share basis. Kalvista Pharmaceuticals employs 33 workers across the globe.

What is Kalvista Pharmaceuticals' official website?

The official website for Kalvista Pharmaceuticals is www.kalvista.com.

How can I contact Kalvista Pharmaceuticals?

Kalvista Pharmaceuticals' mailing address is 55 Cambridge Parkway Suite 901E, CAMBRIDGE MA, 02142. The specialty pharmaceutical company can be reached via phone at 857-999-0075 or via email at [email protected]

This page was last updated on 9/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.